CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

Cumulative X4 Pharmaceuticals Inc's Leverage Ratio for Trailing Twelve Months Period

XFOR's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

XFOR Leverage Ratio for Trailing Twelve Months Period

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Total Liabilities Growth 36.94 % 107.53 % 110.23 % 46.62 % 55.42 %
Leverage Ratio for Trailing Twelve Months Period 2.08 1.38 1.2 1.16 1.06
Total Ranking # 2019 # # 2261 # 2173 # 2317
Seq. Equity Growth -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Total Liabilities Growth 5.19 % -0.13 % 46.35 % -10.93 % 59.42 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2024
On the trailing twelve months basis Due to net new borrowings of 5.19%, Leverage Ratio for Trailing Twelve Months Period improved to 2.08, above X4 Pharmaceuticals Inc's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 69 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than X4 Pharmaceuticals Inc. While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are XFOR's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 70
Sector # 568
S&P 500 # 3125


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
2.11 0.77 0.31
(Mar 31 2024)   (Jun 30 2020)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Atara Biotherapeutics Inc   5.16 
Biocardia Inc  5.05 
Axcella Health Inc   4.67 
Inhibrx Inc   4.55 
Aceragen Inc   4.22 
Protalix Biotherapeutics inc   3.84 
Precision Biosciences Inc  3.68 
Biomx Inc   3.24 
Adaptimmune Therapeutics Plc  3.21 
Champions Oncology Inc   3.10 
Alector Inc   2.94 
Acorda Therapeutics Inc   2.77 
Greenlight Biosciences Holdings Pbc  2.75 
Chromocell Therapeutics Corporation  2.57 
Windtree Therapeutics Inc  2.45 
Valneva Se  2.24 
Pluri Inc   2.10 
Eiger Biopharmaceuticals Inc   2.08 
X4 Pharmaceuticals Inc  1.89 
Curis Inc   1.87 
Meiragtx Holdings Plc  1.81 
Gilead Sciences Inc   1.73 
Immunocore Holdings Plc  1.67 
Humacyte Inc   1.67 
Sutro Biopharma Inc   1.32 
Adma Biologics Inc   1.22 
Orchard Therapeutics Plc  1.21 
Coeptis Therapeutics Holdings Inc   1.15 
Sqz Biotechnologies Company  1.05 
Arcellx Inc   1.00 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com